ELOVL2: A Potential Drug Target and Biomarker (G54898)

Target Name: ELOVL2

NCBI ID: G54898

ELOVL2

ELOVL2: A Potential Drug Target and Biomarker

Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 (ELOVL2) is a phenomenon that has been observed in various organisms, including bacteria, yeast, and even humans. ELOVL2 is a unique fatty acid that is characterized by its elongation, which allows it to have a length of up to 20 carbon atoms. While ELOVL2 has been observed in many organisms, its functions and potential applications are not well understood.

Potential Drug Target

One of the potential applications of ELOVL2 is as a drug target. The elongation of FEN1/Elo2, SUR4/Elo3, and yeast-like 2 (ELOVL2) has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, targeting ELOVL2 may provide new insights into the mechanisms of these diseases and may lead to the development of new treatments.

ELOVL2 as a Biomarker

ELOVL2 has also been shown to be a potential biomarker for various diseases. The elongation of FEN1/Elo2, SUR4/Elo3, and yeast-like 2 (ELOVL2) has been associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, ELOVL2 may be a useful biomarker for the diagnosis and monitoring of these diseases.

ELOVL2 as a Drug

Another potential application of ELOVL2 is as a drug. The elongation of FEN1/Elo2, SUR4/Elo3, and yeast-like 2 (ELOVL2) has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, targeting ELOVL2 may provide new insights into the mechanisms of these diseases and may lead to the development of new treatments.

Conclusion

In conclusion, ELOVL2 is a unique fatty acid that has been observed in various organisms. Its elongation has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, targeting ELOVL2 may provide new insights into the mechanisms of these diseases and may lead to the development of new treatments. Additionally, ELOVL2 has also been shown to be a potential biomarker for the diagnosis and monitoring of various diseases.

Protein Name: ELOVL Fatty Acid Elongase 2

Functions: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that catalyzes the synthesis of polyunsaturated very long chain fatty acid (C20- and C22-PUFA), acting specifically toward polyunsaturated acyl-CoA with the higher activity toward C20:4(n-6) acyl-CoA. May participate in the production of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators

The "ELOVL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOVL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets